Fosamax (Alendronate Sodium) News and Research

RSS

Fosamax (alendronate sodium) is a drug that affects bone metabolism. It is used in treating osteoporosis and Paget's disease, and is being studied in the treatment of hypercalcemia (abnormally high levels of calcium in the blood) and in treating and reducing the risk of bone pain caused by cancer. Alendronate sodium belongs to the family of drugs called bisphosphonates.

$Treatment with zoledronic acid effective in reducing fractures in women with postmenopausal osteoporosis$

Treatment with zoledronic acid effective in reducing fractures in women with postmenopausal osteoporosis

A treatment for osteoporosis delivered once a year is as effective as current monthly or weekly osteoporosis regimens at reducing the incidence of bone fractures, according to a new study led by a UCSF research team.

4 May 2007

Reclast found to cause abnormal heart rhythms

An osteoporosis drug with the potential to cut the risk of spine fractures by 70 percent and the chance of hip fractures by 41 percent, has been found to have an adverse side effect on some women.

3 May 2007

Now OK to get prescription drugs from Canada, but is it really?

According to the consumer group that sponsored "Rx Express" trains to Canada, the U.S. Customs announcement that it will no longer seize prescription drugs being shipped to the U.S. is not the solution that patients need.

5 Oct 2006

More physicians now visit web sites to find information on brand-name prescription drugs

An increased number of physicians visited Web sites that promote brand-name prescription drugs during the first six months of 2006 to seek information about dosages and side effects, according to a recent Manhattan Research study, the Newark Star-Ledger reports.

18 Sep 2006

Study assesses formularies across Medicare drug plans

Medicare's new private stand-alone drug plans vary significantly - in terms of covered drugs, out-of-pocket costs for specific medications, and restrictions placed on the use of certain drugs - according to a new analysis released today by the Kaiser Family Foundation.

11 Apr 2006

Low bone density improved with jabs twice a year

A team of researchers say that women with low bone density can benefit from a twice a year treatment of an experimental drug.

23 Feb 2006

Women with postmenopausal osteoporosis prefer once monthly to weekly treatment

Over 70% of postmenopausal women with Osteoporosis who expressed a preference, preferred once-monthly Bonviva, finding it more convenient than a once-weekly treatment. This is according to new data presented at the 27th Annual Meeting of the American Society for Bone Mineral Research (ASBMR).

26 Sep 2005

Taking parathyroid hormone followed by a year on alendronate shows strong osteoporosis benefit

Postmenopausal women who took a bone-building drug for one year followed by a year on a standard drug that fights bone loss experienced greater increases in bone density than has been reported from any other drug regimen, an NIH-sponsored study has found. Bone density is the standard predictor of fracture risk associated with osteoporosis.

11 Aug 2005

Calcium crucial to benefits of osteoporosis drugs

Although an increasing number of people are taking powerful new prescription drugs to treat osteoporosis, chances are the majority of patients are not getting the greatest effect from these medicines because they do not have an adequate calcium and vitamin D intake, according to a paper published in the March 2005 issue of The Journal of Women's Health.

23 Mar 2005

Link found between bisphosphonates and a serious bone disease called osteonecrosis of the jaw

Doctors at Long Island Jewish (LIJ) Medical Center recently discovered a link between a common chemotherapy drug and a serious bone disease called osteonecrosis of the jaw (ONJ).

13 Dec 2004

Study indicates potential of alendronate and estrogen progression of osteoarthritis

Osteoarthritis (OA) of the knee, a chronic inflammatory disease marked by cartilage degradation and bone abnormalities, is a leading cause of disability among elderly people in the United States.

4 Nov 2004

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people or 10% of the 500,000 people in the U.S with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery for coverage of life saving drugs.

26 Jun 2004